



ASX Company Announcement

Manufacturing Partnership – Test Strips

4 February 2014

The Board of Sun Biomedical (ASX: SBN) is pleased to announce that in addition to the services agreement announced on 21 January 2014 for the manufacture of its “Oraline[®]” test housings, the Company is also in discussions with another manufacturer. The Company has entered into a non-binding Memorandum of Understanding (MoU) with LumiQuick Diagnostics Inc of Santa Clara, California (LumiQuick) and its sister company, Xiamen Boson Biotech Co. Fujian, China (Boson), under which the parties will negotiate the terms for services relating to the development and commercialisation of the Company’s improved Oraline[®] drug test family.

The MoU also allows for the possibility of future cross licensing of the respective parties' products and technologies.

Under the proposal, LumiQuick and Boson will develop saliva test strips compatible with Sun Biomedical’s improved Oraline[®] drug test devices and future products. This agreement will run parallel and complimentary to other manufacturing agreements in place.

“Together with its sister company, Boson Biotech, LumiQuick is a world leading developer and supplier of quality immunoassay based testing products and materials,” said Howard Digby, Chairman of Sun Biomedical. “We are keen to commence this relationship and take it further if it makes mutual sense. LumiQuick has an impressive international distribution footprint and its successful sales and marketing record will bring further value to the relationship. In addition, LumiQuick’s presence in disease diagnostics provides Sun Biomedical with future opportunities in the healthcare sector.”

About Sun Biomedical:

Sun Biomedical Limited is an international biotechnology company with assets in the area of occupational drug testing. The Company is commercialising new improved versions of its “Oraline[®]” hand held multi drug test device while also looking to increase its biotechnology investments.

About LumiQuick:

LumiQuick Diagnostics Inc. (www.lumiquick.com), based in California USA, develops, manufactures and markets high quality point of care tests and other immunoassay kits for the world-wide in-vitro diagnostic market. After many years of development and successful delivery, LumiQuick now offers an extensive range of rapid tests, ELISA, CLIA and raw materials. These product lines provide immunoassay solutions in various formats to detect infectious diseases, cardiac markers, cancer markers, drugs of abuse, fertility hormones and other disease markers. Many products have been CE marked and registered in different countries.

For more information about Sun Biomedical visit its corporate website at www.sunbiomed.com.au

Howard Digby
Executive Chairman
+61 434 987 750